Investor's Business Daily on MSN
Moderna stock gets healthy relative strength rating jump
On Tuesday, Moderna MRNA got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 73. This exclusive rating ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...
Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...
Zacks Investment Research on MSN
Moderna (MRNA) soars 10.9%: Is further upside left in the stock?
Moderna MRNA shares soared 10.9% in the last trading session to close at $35.66. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...
Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback